Drug Trial Radar · NCT03709927
4-way Crossover QT Evaluation in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Mar 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Jan 11, 2018
Primary completion
Apr 12, 2018
Study completion Aug 21, 2018
Sponsor
- Lead sponsor
- Nabriva Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Oct 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate if ZTI-01 (fosfomycin for injection), an investigational drug being developed to treat people with complicated urinary tract and kidney infections, has any effect on the electrical activity of the heart.
Conditions
- Cardiac Repolarization in Healthy Subjects
Interventions
ZTI-01Drug
6g IV fosfomycin
Moxifloxacin 400mgDrug
oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)
Placebo IVOther
IV Placebo (0.9% Normal Saline)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect of ZTI-01 at the therapeutic and supra-therapeutic plasma concentration on cardiac repolarization expressed by QT intervalTime frame: 24 hour Holter ECG at Baseline (Day -1) & day of dosing (Day 1) in each of 4 periods. 10 replicates per time point at 13 timepoints: pre-dose: 60, 45 and 30 minutes; after the start of infusion: 0.5, 1 (end infusion), 1.25, 1.5, 2, 3, 4, 8, 12, & 24 hrs
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.